Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies

Research output: Chapter in Book/Report/Conference proceedingChapter

132 Downloads (Pure)

Abstract

Alzheimer’s disease is an irreversible, neurodegenerative disorder characterized by the progressive loss of memory and thinking skills. A close correlate of this cognitive decline is the aggregation of tau protein, of which neurofibrillary tangles are composed. The process of tau aggregation follows a stereotypical pattern of spread throughout the cortex which begins well before the tangles appear. Autocatalytic capture and assembly of tau into oligomeric aggregates and subsequently into filaments has been replicated in cellular and transgenic models of tau aggregation. It is postulated that in sporadic AD, an age-related defect in mitochondrial turnover producing congestion in the endosomal-lysosomal pathway leads both to nucleation of tau aggregation and decreased capacity of this pathway to clear tau oligomers which are free to propagate further tau aggregation. Upstream intervention aiming to reduce tau entry into the autocatalytic aggregation pathway is predicted to have a purely transient effect. By contrast, disaggregation of oligomers offers the potential to alter the rate of disease progression by facilitating clearance of the constituent monomers through the more efficient proteasomal pathway and bypassing the endosomal-lysosomal pathway. This forms the basis of the rationale for using methylthioninium chloride (MTC) as the first Tau Aggregation Inhibitor, or TAI. MTC has proven effective in reversing both cognitive deficits and tau pathology in transgenic mice. In a phase 2 clinical trial of 321 subjects with mild or moderate AD, MTC reduced the rate of disease progression by 84% over 50 weeks when measured by the ADAS-cog scale.
Original languageEnglish
Title of host publicationEmerging drugs and targets for Alzheimer's disease
Subtitle of host publicationVolume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism
EditorsAna Martinez
Place of PublicationCambridge
Pages210-232
Number of pages23
Volume1
DOIs
Publication statusPublished - 2010

Publication series

NameRSC Drug Discovery Series
PublisherRoyal Society of Chemistry

Fingerprint

Tauopathies
Methylene Blue
Alzheimer Disease
Disease Progression
Mitochondrial Turnover
tau Proteins
Neurofibrillary Tangles
Memory Disorders
Neurodegenerative Diseases
Transgenic Mice
Therapeutics
Clinical Trials
Pathology

Cite this

Wischik, C. M., Wischik, D. J., Storey, J. M. D., & Harrington, C. R. (2010). Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. In A. Martinez (Ed.), Emerging drugs and targets for Alzheimer's disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism (Vol. 1, pp. 210-232). (RSC Drug Discovery Series). Cambridge. https://doi.org/10.1039/9781849731065

Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. / Wischik, Claude M; Wischik, Damon J; Storey, John M D; Harrington, Charles R.

Emerging drugs and targets for Alzheimer's disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism. ed. / Ana Martinez. Vol. 1 Cambridge, 2010. p. 210-232 (RSC Drug Discovery Series).

Research output: Chapter in Book/Report/Conference proceedingChapter

Wischik, CM, Wischik, DJ, Storey, JMD & Harrington, CR 2010, Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. in A Martinez (ed.), Emerging drugs and targets for Alzheimer's disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism. vol. 1, RSC Drug Discovery Series, Cambridge, pp. 210-232. https://doi.org/10.1039/9781849731065
Wischik CM, Wischik DJ, Storey JMD, Harrington CR. Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. In Martinez A, editor, Emerging drugs and targets for Alzheimer's disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism. Vol. 1. Cambridge. 2010. p. 210-232. (RSC Drug Discovery Series). https://doi.org/10.1039/9781849731065
Wischik, Claude M ; Wischik, Damon J ; Storey, John M D ; Harrington, Charles R. / Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. Emerging drugs and targets for Alzheimer's disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism. editor / Ana Martinez. Vol. 1 Cambridge, 2010. pp. 210-232 (RSC Drug Discovery Series).
@inbook{001dbfcae6eb420da7b68e674faba32b,
title = "Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies",
abstract = "Alzheimer’s disease is an irreversible, neurodegenerative disorder characterized by the progressive loss of memory and thinking skills. A close correlate of this cognitive decline is the aggregation of tau protein, of which neurofibrillary tangles are composed. The process of tau aggregation follows a stereotypical pattern of spread throughout the cortex which begins well before the tangles appear. Autocatalytic capture and assembly of tau into oligomeric aggregates and subsequently into filaments has been replicated in cellular and transgenic models of tau aggregation. It is postulated that in sporadic AD, an age-related defect in mitochondrial turnover producing congestion in the endosomal-lysosomal pathway leads both to nucleation of tau aggregation and decreased capacity of this pathway to clear tau oligomers which are free to propagate further tau aggregation. Upstream intervention aiming to reduce tau entry into the autocatalytic aggregation pathway is predicted to have a purely transient effect. By contrast, disaggregation of oligomers offers the potential to alter the rate of disease progression by facilitating clearance of the constituent monomers through the more efficient proteasomal pathway and bypassing the endosomal-lysosomal pathway. This forms the basis of the rationale for using methylthioninium chloride (MTC) as the first Tau Aggregation Inhibitor, or TAI. MTC has proven effective in reversing both cognitive deficits and tau pathology in transgenic mice. In a phase 2 clinical trial of 321 subjects with mild or moderate AD, MTC reduced the rate of disease progression by 84{\%} over 50 weeks when measured by the ADAS-cog scale.",
author = "Wischik, {Claude M} and Wischik, {Damon J} and Storey, {John M D} and Harrington, {Charles R}",
year = "2010",
doi = "10.1039/9781849731065",
language = "English",
isbn = "978-1-84973-106-5",
volume = "1",
series = "RSC Drug Discovery Series",
publisher = "Royal Society of Chemistry",
pages = "210--232",
editor = "Ana Martinez",
booktitle = "Emerging drugs and targets for Alzheimer's disease",

}

TY - CHAP

T1 - Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies

AU - Wischik, Claude M

AU - Wischik, Damon J

AU - Storey, John M D

AU - Harrington, Charles R

PY - 2010

Y1 - 2010

N2 - Alzheimer’s disease is an irreversible, neurodegenerative disorder characterized by the progressive loss of memory and thinking skills. A close correlate of this cognitive decline is the aggregation of tau protein, of which neurofibrillary tangles are composed. The process of tau aggregation follows a stereotypical pattern of spread throughout the cortex which begins well before the tangles appear. Autocatalytic capture and assembly of tau into oligomeric aggregates and subsequently into filaments has been replicated in cellular and transgenic models of tau aggregation. It is postulated that in sporadic AD, an age-related defect in mitochondrial turnover producing congestion in the endosomal-lysosomal pathway leads both to nucleation of tau aggregation and decreased capacity of this pathway to clear tau oligomers which are free to propagate further tau aggregation. Upstream intervention aiming to reduce tau entry into the autocatalytic aggregation pathway is predicted to have a purely transient effect. By contrast, disaggregation of oligomers offers the potential to alter the rate of disease progression by facilitating clearance of the constituent monomers through the more efficient proteasomal pathway and bypassing the endosomal-lysosomal pathway. This forms the basis of the rationale for using methylthioninium chloride (MTC) as the first Tau Aggregation Inhibitor, or TAI. MTC has proven effective in reversing both cognitive deficits and tau pathology in transgenic mice. In a phase 2 clinical trial of 321 subjects with mild or moderate AD, MTC reduced the rate of disease progression by 84% over 50 weeks when measured by the ADAS-cog scale.

AB - Alzheimer’s disease is an irreversible, neurodegenerative disorder characterized by the progressive loss of memory and thinking skills. A close correlate of this cognitive decline is the aggregation of tau protein, of which neurofibrillary tangles are composed. The process of tau aggregation follows a stereotypical pattern of spread throughout the cortex which begins well before the tangles appear. Autocatalytic capture and assembly of tau into oligomeric aggregates and subsequently into filaments has been replicated in cellular and transgenic models of tau aggregation. It is postulated that in sporadic AD, an age-related defect in mitochondrial turnover producing congestion in the endosomal-lysosomal pathway leads both to nucleation of tau aggregation and decreased capacity of this pathway to clear tau oligomers which are free to propagate further tau aggregation. Upstream intervention aiming to reduce tau entry into the autocatalytic aggregation pathway is predicted to have a purely transient effect. By contrast, disaggregation of oligomers offers the potential to alter the rate of disease progression by facilitating clearance of the constituent monomers through the more efficient proteasomal pathway and bypassing the endosomal-lysosomal pathway. This forms the basis of the rationale for using methylthioninium chloride (MTC) as the first Tau Aggregation Inhibitor, or TAI. MTC has proven effective in reversing both cognitive deficits and tau pathology in transgenic mice. In a phase 2 clinical trial of 321 subjects with mild or moderate AD, MTC reduced the rate of disease progression by 84% over 50 weeks when measured by the ADAS-cog scale.

U2 - 10.1039/9781849731065

DO - 10.1039/9781849731065

M3 - Chapter

SN - 978-1-84973-106-5

VL - 1

T3 - RSC Drug Discovery Series

SP - 210

EP - 232

BT - Emerging drugs and targets for Alzheimer's disease

A2 - Martinez, Ana

CY - Cambridge

ER -